Background for Promotions.png

WEBINAR SERIES

Obtaining High Quality Imaging Data from Clinical Trials

In this webinar, we discuss how to obtain high-quality imaging data and the benefits medical imaging provides to your drug discovery and development pipelines. We take a deeper dive into:
  • Examining the process of site set-up and qualification and the importance of choosing the right imaging partner at the start of your trial
  • The role of standardized site-training, including web-based training platforms and the effects on obtaining high quality imaging data
  • The importance of phantom management and analysis of data to assess performance of scanners prior to the start of your study
Justin Albani | Director of Imaging Services, Invicro
Lino Becerra, Ph.D. | Vice President MRI, Invicro

About The Speakers

Justin Albani
Director of Imaging Services, Invicro

Justin Albani has over ten years of experience in clinical research and medical imaging, where he focused on imaging operations and data collection, review, and standardization. At Invicro, Justin is responsible for the oversight of global training and imaging equipment qualification across centers participating in Phase I -III clinical trials, as well as imaging data receipt and processing.

LINO BECERRA, PH.D.
Vice President MRI, Invicro

Lino Becerra, Ph.D. serves as Vice President of MRI to further consolidate and expand Invicro's capabilities to support studies utilizing MRI techniques from preclinical to clinical trials. Previously, Lino was the Co-Director for The Center for Pain and the Brain at Harvard Medical School as well as being a faculty member for over 20 years. He has worked extensively in neuroimaging applications in neurological conditions. He Co-Founded Descartes Therapeutics Inc., a biotech company that was dedicated to the development of drugs for chronic pain and was Co-Director of the Imaging Consortium for Drug Development, which was formed by Harvard, McLean Hospital, Massachusetts General Hospital, Merck, Eli Lilly and Sepracor Pharmaceuticals.